Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial Abb. 2: MICARDIS ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial Aktuelles Bild - Abb. 3: ONTARGET trial programme Abb. 4: ONTARGET - background Abb. 5: ONTARGET - background Abb. 6: ONTARGET - from HOPE to ONTARGET Zum letzten Bild
Abbildung 3: ONTARGET trial programme
The ONTARGET Trial Programme will involve a total of 28,400 patients and will include two parallel studies. ONTARGET, the Micardis trial in cardiovascular protection. This is the principal trial in the ONTARGET Trial Programme and will involve 23,400 patients. TRANSCEND is the parallel study of ONTARGET which will assess the protective effects of telmisartan in 5000 patients intolerant to angiotensin converting enzyme (ACE) inhibitors.
 
ONTARGET trial programme
Vorheriges Bild Nächstes Bild   


Abbildung 3: ONTARGET trial programme
The ONTARGET Trial Programme will involve a total of 28,400 patients and will include two parallel studies. ONTARGET, the Micardis trial in cardiovascular protection. This is the principal trial in the ONTARGET Trial Programme and will involve 23,400 patients. TRANSCEND is the parallel study of ONTARGET which will assess the protective effects of telmisartan in 5000 patients intolerant to angiotensin converting enzyme (ACE) inhibitors.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung